Search Results 1031-1040 of 3698 for Solid

1. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

   Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria is required except for subjects with bone only disease. All prior ...

2. A Study of the Effectiveness and Safety of Pembrolizumab (MK-3475) for Women with Advanced Recurrent Ovarian Cancer - Mayo Clinic

   ... Solid Tumors (RECIST) 1.1 as determined by the central imaging vendor; Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Has a ...

3. A Study in Second Line Metastatic Colorectal Cancer - Mayo Clinic

   ... Solid Tumors, Version 1.1 (RECIST v1.1); Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; Adequate hematologic, renal and hepatic ...

4. Clinical trials - Oncology (Medical)

   Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of ...

5. Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure - Mayo Clinic

   Subject with a current malignancy including solid tumors and hematologic malignancies whose thrombocytopenia may be attributed to chemotherapy. Hepatic ...

6. Cancer treatment - Mayo Clinic

   Unleashing CAR-T cell therapy to destroy solid tumors in thyroid cancer · Teamwork and a new nickname inspire patient through pancreatic cancer treatment · Mayo ...

7. Clinical trials - Oncology (Medical)

   Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of ...

8. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

   Prior solid organ transplantation. Prior therapy with any known inhibitor of MNK1 orMNK2. Ongoing immunosuppressive therapy, including systemic or enteric ...

9. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors - Mayo Clinic

   ... Solid Tumors (RECIST) version (v)1.1 criteria in the 12 months prior to registration; the radiologic images, imaging reports, and clinic notes indicating ...

10. Clinical trials - Oncology (Medical)

    ... Solid Tumors version 1.1 (RECIST 1.1) after initial treatment. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter ...